

CYCLE 1
SERIAL PK
SERIAL PK
PRE-DOSE
CYCLE 1
DAY
-3
1
2
3
4
5
CYCLE ≥ 2
ASTX727
DAYS 1-5
Q 28
DAYS
DAC+E7727 ORAL COMBINATION
DAC ORAL ALONE
DAC IV INFUSION 1-h 20mg/m2
ESCALATE ONE DRUG PER COHORT STARTING DOSE (40 mg CEDAZURIDINE/20 mg DAC)
DAC=DECITABINE

FIG. 1



MEAN DECITABINE CONCENTRATION, ng/mL
200
150
100
50
0
0
2
4
6
8
TIME, h
C 40 mg DEC 20 mg
C 60 mg DEC 20 mg
C 100 mg DEC 20 mg
C 100 mg DEC 40 mg
C 100 mg DEC 30 mg
DEC ALONE, 20 mg
IV DEC ALONE, 20 mg/m2
DEC ALONE, 40 mg
DEC ALONE, 30 mg

FIG. 2



SUBJECTS WITH IPSS INTERMEDIATE-1,-2, OR HIGH-RISK MDS
N=80
DECITABINE IV 20 mg/m2
ASTX727* 35 mg DECITABINE + 100 mg E7727
CYCLE 1
DECITABINE IV 20 mg/m2
ASTX727* 35 mg DECITABINE + 100 mg E7727
CYCLE 2

FIG. 3



INDIVIDUAL AUC0-24 (ORAL)
GEOMETRIC MEAN AUC0-24 (ORAL)
INDIVIDUAL AUC0-24 (IV)
IV GEOMEAN
PLASMA DECITABINE AUC0-24 (h*ng/mL)
1000
100
10
DAY 1
DAY 2
DAY 5
IV

FIG. 4



ASTX727 COURSE 1
RELATIVE LINE-1 DEMETHYLATION (%)
0
-5
-10
-15
1
8
15
22
COURSE DAY

FIG. 5A



IV DAC COURSE 2
RELATIVE LINE-1 DEMETHYLATION (%)
0
-5
-10
-15
1
8
15
22
COURSE DAY

FIG. 5B



IV DAC COURSE 1
RELATIVE LINE-1 DEMETHYLATION (%)
0
-5
-10
-15
1
8
15
22
COURSE DAY

FIG. 6A



ASTX727 COURSE 2
RELATIVE LINE-1 DEMETHYLATION (%)
0
-5
-10
-15
1
8
15
22
COURSE DAY

FIG. 6B



(INT/HIGH RISK MDS; CMML; AML 20–30% BLASTS)
Ascertain
MDS and CMML
AT LEAST 118
EVALUABLE PATIENTS
WITH ADEQUATE PK IN
CYCLES 1 AND 2
RANDOM-
IZATION
1:1
SEQUENCE A
SEQUENCE B
CYCLE 1
ORAL ASTX727
1 TABLET X 5 D
IV DECITABINE
1 h IV INFUSION X 5 D
CYCLE 2
IV DECITABINE
1 h IV INFUSION X5 D
ORAL ASTX727
1 TABLET X 5 D
≥3 CYCLES
ORAL ASTX727
1 TABLET X 5 D

FIG. 7



ORAL ASTX727
IV DEC
1000
100
10
PLASMA DEC AUC0-24 (h·ng/mL)
INDIVIDUAL
GEOMETRIC MEAN
DAY 1
DAY 2
DAY 5
DAY 1
DAY 5

FIG. 8



CYCLE 1
(N=62)
CYCLE 2
(N=63)
0
-2
-4
-6
-8
-10
-12
-14
-16
-18
MAX. %LINE-1 DEMETHYLATION
LSM (95% CI)
-13.3%
-14.0%
Δ-0.7%
-11.2%
-12.0%
Δ-0.8%
ASTX727
IV DECITABINE

FIG. 9